RPTX — Repare Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
Repare Therapeutics Inc (RPTX) is a biotechnology company listed on NASDAQ. It is led by Steve Forte CPA, based in 7171 Frederick-Banting, Building 2, Montreal, QC, Canada, H4S 1Z9, with about 129 employees. Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.
Net income was $3.3M. RPTX currently screens at market cap $61.8M.
Use this RPTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RPTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RPTX SEC filings page. Lician reads the product cache first so this HTML stays unique to Repare Therapeutics Inc even when a live quote feed is slow.
About Repare Therapeutics Inc
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.
RPTX Key Statistics
Market Cap
$61.76M
EPS
-$2.00
Revenue
$0.00
Net Income
-$84.69M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
129
RPTX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$84.69M | -$93.80M | -$29.05M | -$106.91M |
| EPS (Diluted) | -$2.00 | -$2.23 | -$0.69 | -$2.83 |
Total Assets
$176.51M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$84.72M
Operating Cash Flow
-$76.44M
Free Cash Flow
$0.00
Repare Therapeutics Inc Company Information
- President, CFO, CEO & Director
- Steve Forte CPA
- Headquarters
- 7171 Frederick-Banting, Building 2, Montreal, QC, Canada, H4S 1Z9
- Website
- www.reparerx.com
- Phone
- 857-412-7018
- IPO / Founded
- 2020-06-19
- Sector
- Healthcare
- Industry
- Biotechnology